MSFT 414.2 2.0901% AAPL 220.11 -0.3621% NVDA 108.1 1.5309% GOOGL 148.66 -0.0336% GOOG 150.01 0.3143% AMZN 179.55 2.366% META 504.79 0.0% AVGO 148.21 5.2478% TSLA 226.17 4.5776% TSM 162.43 -0.215% LLY 901.25 -0.7729% V 285.34 -0.0945% JPM 205.56 -5.1889% UNH 599.03 0.8298% NVO 129.78 -1.6147% WMT 78.81 1.9007% LVMUY 135.45 -0.7401% XOM 110.82 -3.6432% LVMHF 676.0 -1.0402% MA 488.02 0.1909%
Last update at 2024-09-11T00:17:00Z
QuidelOrtho Appoints Lee Bowman as Chief Human Resources Officer
Tue 10 Sep 24, 11:00 AMIs Jana Partners Starting an Activist Campaign Against QuidelOrtho Corporation (QDEL)?
Tue 13 Aug 24, 08:55 PMShareholders in QuidelOrtho (NASDAQ:QDEL) are in the red if they invested three years ago
Fri 09 Aug 24, 12:40 PMQuidelOrtho Reports Second Quarter 2024 Financial Results
Wed 31 Jul 24, 08:05 PMAvantor Set to Join S&P MidCap 400; QuidelOrtho & Schneider National to Join S&P SmallCap 600
Tue 23 Jul 24, 11:17 PMQuidelOrtho to Report Second Quarter 2024 Financial Results
Wed 17 Jul 24, 11:00 AMHarvest ETFs June 2021 Distributions
Mon 21 Jun 21, 11:30 AMBreakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | 735.90M | 900.36M | 1040.32M | 77.18M | 63.38M |
Minority interest | - | - | - | - | - |
Net income | 548.70M | 704.23M | 810.29M | 72.92M | 74.18M |
Selling general administrative | 621.00M | 84.25M | 66.59M | 52.76M | 44.95M |
Selling and marketing expenses | - | 175.32M | 133.96M | 111.11M | 108.99M |
Gross profit | 1936.00M | 1270.89M | 1348.86M | 320.81M | 315.71M |
Reconciled depreciation | 132.50M | 54.38M | 49.09M | 51.79M | 46.27M |
Ebit | 843.70M | 906.07M | 1060.33M | 52.59M | 63.86M |
Ebitda | 1104.10M | 915.62M | 1064.02M | 104.38M | 110.13M |
Depreciation and amortization | 260.40M | 9.56M | 3.69M | 51.79M | 46.27M |
Non operating income net other | - | -5.70600M | -20.00700M | -15.53800M | -32.54500M |
Operating income | 843.70M | 906.07M | 1060.33M | 52.59M | 95.93M |
Other operating expenses | 2286.30M | 782.93M | 597.65M | 430.51M | 412.16M |
Interest expense | 75.70M | 5.71M | 9.62M | 14.79M | 24.28M |
Tax provision | 187.20M | 196.13M | 230.03M | 4.26M | -10.79900M |
Interest income | 1.30M | - | - | 14.79M | 24.28M |
Net interest income | -75.70000M | -5.70600M | -9.62300M | -14.79000M | -24.28300M |
Extraordinary items | - | - | - | - | - |
Non recurring | - | -9.55700M | -3.69400M | -11.66700M | -14.19700M |
Other items | - | - | - | - | - |
Income tax expense | 187.20M | 196.13M | 230.03M | 4.26M | -10.79900M |
Total revenue | 3266.00M | 1698.55M | 1661.67M | 534.89M | 522.28M |
Total operating expenses | 956.30M | 355.27M | 284.83M | 216.42M | 205.59M |
Cost of revenue | 1330.00M | 427.66M | 312.81M | 214.09M | 206.57M |
Total other income expense net | -107.80000M | -5.70600M | -20.00700M | 24.59M | -22.45900M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | 548.70M | 704.23M | 810.29M | 72.92M | 74.18M |
Net income applicable to common shares | 548.70M | 704.23M | 810.29M | 72.92M | 74.18M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
Total assets | 8563.10M | 8855.80M | 2430.37M | 1871.16M | 910.87M |
Intangible assets | 2934.30M | 3123.80M | 98.66M | 122.43M | 148.11M |
Earning assets | - | - | - | - | - |
Other current assets | 77.00M | 252.10M | 4.59M | 2.16M | 1.89M |
Total liab | 3557.20M | 3921.20M | 501.01M | 538.46M | 351.05M |
Total stockholder equity | 5005.90M | 4934.60M | 1929.36M | 1332.70M | 559.82M |
Deferred long term liab | - | 3.50M | 36.49M | 73.95M | 109.38M |
Other current liab | 335.70M | 439.80M | 210.07M | 239.11M | 78.62M |
Common stock | 0.10M | - | 0.04M | 0.04M | 0.04M |
Capital stock | 0.10M | 0.00000M | 0.04M | 0.04M | 0.04M |
Retained earnings | 2187.80M | 2197.90M | 1649.20M | 944.97M | 134.68M |
Other liab | - | 294.90M | 48.58M | 96.69M | 127.55M |
Good will | 2492.00M | 2476.80M | 337.02M | 337.03M | 337.02M |
Other assets | - | 395.80M | 39.71M | 158.82M | 31.63M |
Cash | 118.90M | 292.90M | 802.75M | 489.94M | 52.77M |
Cash and equivalents | - | - | - | - | - |
Total current liabilities | 833.80M | 1007.00M | 323.52M | 336.96M | 125.89M |
Current deferred revenue | 36.80M | 76.40M | 1.92M | 3.73M | 1.50M |
Net debt | 2495.20M | 2531.80M | -664.15600M | -381.43600M | 59.52M |
Short term debt | 166.50M | 207.50M | 10.04M | 7.80M | 19.07M |
Short long term debt | 139.80M | 207.50M | - | - | 12.66M |
Short long term debt total | 2614.10M | 2824.70M | 138.59M | 108.50M | 112.30M |
Other stockholder equity | 2848.00M | 2804.30M | 279.77M | 388.12M | 425.56M |
Property plant equipment | - | 1520.00M | 349.20M | 110.48M | 79.76M |
Total current assets | 1310.50M | 1575.10M | 1440.31M | 1142.40M | 222.23M |
Long term investments | 7.40M | 21.00M | 37.85M | - | - |
Net tangible assets | - | -666.00000M | 1622.24M | 973.95M | 167.92M |
Short term investments | 48.40M | 52.10M | 25.76M | - | - |
Net receivables | 488.40M | 453.90M | 393.85M | 529.17M | 104.91M |
Long term debt | 2274.80M | 2430.80M | - | - | - |
Inventory | 577.80M | 524.10M | 198.76M | 113.80M | 58.09M |
Accounts payable | 294.80M | 283.30M | 101.49M | 86.32M | 26.70M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | -30.00000M | -67.60000M | 0.35M | -0.43100M | -0.46300M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | - | - | 0.04M | 0.04M | 0.04M |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | - | - | 1649.20M | 944.97M | 134.68M |
Treasury stock | - | - | - | - | - |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 179.00M | 122.70M | 19.62M | 13.51M | 7.13M |
Deferred long term asset charges | - | - | - | - | 24.50M |
Non current assets total | 7252.60M | 7280.70M | 990.06M | 728.76M | 688.64M |
Capital lease obligations | 199.50M | 186.40M | 138.59M | 108.50M | 99.64M |
Long term debt total | - | - | - | - | 4.38M |
Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
Investments | -187.60000M | -1644.20000M | -63.68700M | -63.32200M | -27.22900M |
Change to liabilities | - | 23.50M | -23.33700M | 220.19M | 7.36M |
Total cashflows from investing activities | - | -1644.20000M | -319.53000M | -63.32200M | -27.22900M |
Net borrowings | - | 346.20M | -0.26000M | -0.51100M | -54.29200M |
Total cash from financing activities | -265.80000M | 252.00M | -173.17700M | -130.27700M | -98.28200M |
Change to operating activities | - | -83.20000M | 19.65M | 15.99M | 9.24M |
Net income | -10.10000M | 548.70M | 704.23M | 810.29M | 72.92M |
Change in cash | -174.00000M | -508.90000M | 312.81M | 437.17M | 9.08M |
Begin period cash flow | 292.90M | 802.80M | 489.94M | 52.77M | 43.70M |
End period cash flow | 118.90M | 293.90M | 802.75M | 489.94M | 52.77M |
Total cash from operating activities | 280.20M | 885.30M | 805.87M | 629.76M | 134.49M |
Issuance of capital stock | 11.60M | 26.40M | 7.55M | 9.61M | 14.78M |
Depreciation | 457.20M | 283.60M | 54.38M | 49.09M | 51.79M |
Other cashflows from investing activities | - | 18.40M | 36.88M | 1.60M | 1.60M |
Dividends paid | - | - | - | - | - |
Change to inventory | -211.60000M | -116.90000M | -85.03900M | -54.90300M | 9.14M |
Change to account receivables | 160.00M | 150.20M | 118.85M | -402.09400M | -36.05900M |
Sale purchase of stock | -7.20000M | -74.30000M | -103.43800M | -47.88900M | -10.72800M |
Other cashflows from financing activities | -43.80000M | 2688.20M | -77.02900M | -48.04400M | -48.77700M |
Change to netincome | - | 106.20M | 50.08M | 12.28M | 13.74M |
Capital expenditures | 209.30M | 140.90M | 292.72M | 64.93M | 27.23M |
Change receivables | - | - | 118.85M | -402.09400M | -36.05900M |
Cash flows other operating | - | - | -13.69900M | -5.85600M | 14.01M |
Exchange rate changes | - | - | - | - | 0.11M |
Cash and cash equivalents changes | - | - | 313.16M | 436.16M | 9.08M |
Change in working capital | -194.90000M | -53.20000M | -2.78000M | -251.06800M | -15.23900M |
Stock based compensation | 51.60M | 48.40M | 25.40M | 21.02M | 13.25M |
Other non cash items | -72.20000M | 57.80M | -0.04000M | 20.65M | 13.50M |
Free cash flow | 70.90M | 744.40M | 513.14M | 564.84M | 107.26M |
Sector: Healthcare Industry: Medical Devices
Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
QDEL Quidel Corporation |
-0.56 1.25% | 44.12 | - | 15.41 | 0.94 | 0.56 | 1.76 | 8.68 |
ABT Abbott Laboratories |
0.68 0.58% | 117.11 | 37.15 | 23.15 | 4.67 | 4.97 | 4.88 | 19.38 |
SYK Stryker Corporation |
2.27 0.63% | 365.05 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
MDT Medtronic PLC |
0.37 0.41% | 90.99 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
BSX Boston Scientific Corp |
0.41 0.50% | 83.06 | 68.17 | 24.57 | 5.85 | 4.26 | 6.46 | 26.80 |
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
9975 Summers Ridge Road, San Diego, CA, United States, 92121
Name | Title | Year Born |
---|---|---|
Mr. Douglas C. Bryant | Chairman & CEO | 1958 |
Mr. Robert J. Bujarski J.D. | Pres & COO | 1969 |
Ms. Michelle A. Hodges | Gen. Counsel | 1960 |
Dr. Werner Kroll Ph.D. | Sr. VP of R&D | 1957 |
Mr. Joseph M. Busky CPA | Chief Financial Officer | 1968 |
Ms. Louise Brandy | Chief Information Officer | NA |
Mr. Patrick E. Klein | Chief Admin. Officer | NA |
Ruben Argueta | Director of Investor Relations | NA |
Mr. Michael S. Iskra | Chief Commercial Officer | 1970 |
Phillip S. Askim | VP, Associate Gen. Counsel & Sec. | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.